Neurocrine Receives FDA Investigational New Drug Acceptance For NBI-1117567 Phase 2 Alzheimer's Study, Triggering $10M Payment To Nxera

Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

NBIX

0.00
  • NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine
  • Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall milestone package
  • Nxera retains development and commercialization rights to the M1 receptor agonist for all indications in Japan
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.